MedTrace Logo

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-07-27

No results posted yet for this study

Summary

Adaptive Biotechnologies has developed a clinical test called T-Detect COVID Test that can identify a T-cell response to the SARS-CoV-2 virus, indicating recent or prior infection This study aims to evaluate the potential cross-reactivity of the T-Detect COVID test in participants presenting with viral upper respiratory tract infections within the assay's intended use population and testing positive for seasonal coronavirus.

Conditions

Sponsors & Collaborators

  • Adaptive Biotechnologies

    lead INDUSTRY

Principal Investigators

  • Darcy Gill · Adaptive Biotechnologies

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2023-05-17
Completion
2023-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112874 on ClinicalTrials.gov